LMR Partners’s Solid Biosciences SLDB Stock Holding History

LMR Partners’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,890	Closed	-$17K	–	1294
2022 Q2	$17K	Buy	+1,890	New	+$19.6K	﹤0.01%	1242

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

LMR Partners's SLDB Position: Q3 2022 in Review

LMR Partners sold out of Solid Biosciences (SLDB) in Q3 2022, closing a stake of 1,890 shares — an estimated $17K sold.

LMR Partners first reported a position in SLDB in Q2 2022 and held it in 1 quarter. The position peaked at $17K in Q2 2022. 58 funds tracked by Wall St. Rank hold SLDB as of Q3 2022.

LMR Partners reported no remaining Solid Biosciences position as of Q3 2022 after selling out during the quarter.
LMR Partners sold 1,890 Solid Biosciences shares in Q3 2022, an estimated $17K.
LMR Partners first reported a position in Solid Biosciences in Q2 2022 and held it in 1 quarter.
LMR Partners's Solid Biosciences position peaked at $17K in Q2 2022.
58 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2022.

Based on LMR Partners's 13F filing for Q3 2022, filed 14 Nov 2022.